Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

    ... myelodysplastic syndrome patients treated with azacitidine (AZA) remain largely unknown. Two hundred eighty-two ...

    Research Article last updated 07/28/2014 - 8:53am.

  2. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

    ... syndromes with excess blasts after failure of azacitidine or decitabine treatment. METHODS: We did this ...

    Research Article last updated 06/07/2016 - 11:10am.

  3. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine

    ... Center Clinical Database who received lenalidomide and azacitidine after ESA treatment failure. Rates of erythroid hematologic ... in patients who received lenalidomide first followed by azacitidine (group 1) and those who received lenalidomide after azacitidine ...

    Research Article last updated 12/09/2015 - 8:59am.

  4. Recent developments in myelodysplastic syndromes

    ... in the United States (US). US regulatory approval of azacitidine , decitabine , and lenalidomide between 2004 and ...

    Research Article last updated 04/29/2016 - 11:34am.

  5. Myelodysplastic syndromes: Contemporary review and how we treat

    ... limited; they include the hypomethylating agents (HMA) azacitidine and decitabine and lenalidomide for MDS with ...

    Research Article last updated 04/29/2016 - 1:05pm.

  6. Personalized medicine for MDS

    ... accordingly. -Hypomethylating agents, such as azacitidine and decitabine , are standard care for older patients ... MDS who are not candidates for stem cell transplant.  Azacitidine in particular has been shown to have a survival advantage compared ...

    Research Review last updated 05/02/2016 - 9:44am.

  7. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

    ... The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently ... myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is ...

    Research Article last updated 11/19/2015 - 8:32am.

  8. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.

    ... describing common adverse events (AEs) associated with azacitidine and methods to manage them. METHODS: In the Cancer ... (FAB) subtype of MDS were randomized to azacitidine or best supportive care (BSC). After 56 d, patients ... to BSC with disease progression could cross over to receive azacitidine. In the AZA-001 study, patients with higher-risk MDS (FAB-defined ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents

    ... myelodysplastic syndrome (MDS) patients in whom azacitidine was the only treatment to demonstrate an overall survival ...

    Research Article last updated 09/29/2015 - 2:12pm.

  10. CASCADE (SGN33A-005)

    ... talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine extends overall survival longer than placebo combined with either azacitidine or decitabine. ...

    Clinical Trial last updated 06/19/2017 - 2:43pm.